NASDAQ:ICPT

Intercept Pharmaceuticals Competitors

$21.20

-0.34 (-1.58 %)

(As of 04/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$20.96

Now: $21.20▼

$21.89

50-Day Range

$19.33

MA: $22.12▼

$24.88

52-Week Range

$18.15

Now: $21.20▼

$95.98

Volume734,045 shs

Average Volume1.17 million shs

Market Capitalization$703.03 million

P/E RatioN/A

Dividend YieldN/A

Beta1.85

Intercept Pharmaceuticals (NASDAQ:ICPT) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying ICPT stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Intercept Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Intercept Pharmaceuticals vs. Amgen Stock

Amgen (NASDAQ:AMGN) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Amgen and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amgen	29.42%	95.55%	15.52%
Intercept Pharmaceuticals	-106.64%	-1,973.10%	-48.51%

Valuation and Earnings

This table compares Amgen and Intercept Pharmaceuticals' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$23.36 billion	6.29	$7.84 billion	$14.82	17.21
Intercept Pharmaceuticals	$252 million	2.79	$-344,680,000.00	($10.89)	-1.95

Amgen has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.2% of Amgen shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Amgen and Intercept Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	0	9	14	0	2.61
Intercept Pharmaceuticals	1	15	8	0	2.29

Amgen presently has a consensus target price of $261.1429, suggesting a potential upside of 2.38%. Intercept Pharmaceuticals has a consensus target price of $50.6957, suggesting a potential upside of 139.02%. Given Intercept Pharmaceuticals' higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Amgen.

Risk and Volatility

Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

Summary

Amgen beats Intercept Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Intercept Pharmaceuticals vs. Gilead Sciences Stock

Gilead Sciences (NASDAQ:GILD) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Gilead Sciences and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	5.48%	37.77%	12.76%
Intercept Pharmaceuticals	-106.64%	-1,973.10%	-48.51%

Valuation and Earnings

This table compares Gilead Sciences and Intercept Pharmaceuticals' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$22.45 billion	3.68	$5.39 billion	$6.14	10.69
Intercept Pharmaceuticals	$252 million	2.79	$-344,680,000.00	($10.89)	-1.95

Gilead Sciences has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Gilead Sciences and Intercept Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	1	9	13	0	2.52
Intercept Pharmaceuticals	1	15	8	0	2.29

Gilead Sciences presently has a consensus target price of $97.68, suggesting a potential upside of 48.79%. Intercept Pharmaceuticals has a consensus target price of $50.6957, suggesting a potential upside of 139.02%. Given Intercept Pharmaceuticals' higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Gilead Sciences.

Risk and Volatility

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

Summary

Gilead Sciences beats Intercept Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Intercept Pharmaceuticals vs. Vertex Pharmaceuticals Stock

Vertex Pharmaceuticals (NASDAQ:VRTX) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Vertex Pharmaceuticals and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	38.51%	28.55%	20.68%
Intercept Pharmaceuticals	-106.64%	-1,973.10%	-48.51%

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Intercept Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$4.16 billion	13.43	$1.18 billion	$4.29	50.34
Intercept Pharmaceuticals	$252 million	2.79	$-344,680,000.00	($10.89)	-1.95

Vertex Pharmaceuticals has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Vertex Pharmaceuticals and Intercept Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0	4	21	1	2.88
Intercept Pharmaceuticals	1	15	8	0	2.29

Vertex Pharmaceuticals currently has a consensus price target of $293.2083, indicating a potential upside of 35.76%. Intercept Pharmaceuticals has a consensus price target of $50.6957, indicating a potential upside of 139.02%. Given Intercept Pharmaceuticals' higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Summary

Vertex Pharmaceuticals beats Intercept Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Intercept Pharmaceuticals vs. Regeneron Pharmaceuticals Stock

Regeneron Pharmaceuticals (NASDAQ:REGN) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Regeneron Pharmaceuticals and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	38.28%	28.97%	20.11%
Intercept Pharmaceuticals	-106.64%	-1,973.10%	-48.51%

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Intercept Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$7.86 billion	6.68	$2.12 billion	$21.47	22.84
Intercept Pharmaceuticals	$252 million	2.79	$-344,680,000.00	($10.89)	-1.95

Regeneron Pharmaceuticals has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Regeneron Pharmaceuticals and Intercept Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0	5	14	1	2.80
Intercept Pharmaceuticals	1	15	8	0	2.29

Regeneron Pharmaceuticals currently has a consensus price target of $644.1739, indicating a potential upside of 31.90%. Intercept Pharmaceuticals has a consensus price target of $50.6957, indicating a potential upside of 139.02%. Given Intercept Pharmaceuticals' higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Intercept Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Intercept Pharmaceuticals vs. Biogen Stock

Biogen (NASDAQ:BIIB) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Biogen and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biogen	35.63%	51.00%	23.54%
Intercept Pharmaceuticals	-106.64%	-1,973.10%	-48.51%

Volatility and Risk

Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Institutional & Insider Ownership

83.5% of Biogen shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Biogen and Intercept Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$14.38 billion	2.74	$5.89 billion	$33.57	7.72
Intercept Pharmaceuticals	$252 million	2.79	$-344,680,000.00	($10.89)	-1.95

Biogen has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Biogen and Intercept Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	5	14	12	0	2.23
Intercept Pharmaceuticals	1	15	8	0	2.29

Biogen currently has a consensus price target of $303.3103, indicating a potential upside of 17.00%. Intercept Pharmaceuticals has a consensus price target of $50.6957, indicating a potential upside of 139.02%. Given Intercept Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Biogen.

Summary

Biogen beats Intercept Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Intercept Pharmaceuticals vs. Alexion Pharmaceuticals Stock

Alexion Pharmaceuticals (NASDAQ:ALXN) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Alexion Pharmaceuticals and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alexion Pharmaceuticals	16.32%	23.16%	14.76%
Intercept Pharmaceuticals	-106.64%	-1,973.10%	-48.51%

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Institutional & Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Alexion Pharmaceuticals and Intercept Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alexion Pharmaceuticals	$4.99 billion	7.42	$2.40 billion	$9.74	17.21
Intercept Pharmaceuticals	$252 million	2.79	$-344,680,000.00	($10.89)	-1.95

Alexion Pharmaceuticals has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Alexion Pharmaceuticals and Intercept Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alexion Pharmaceuticals	0	17	4	1	2.27
Intercept Pharmaceuticals	1	15	8	0	2.29

Alexion Pharmaceuticals currently has a consensus price target of $153.4286, indicating a potential downside of 8.44%. Intercept Pharmaceuticals has a consensus price target of $50.6957, indicating a potential upside of 139.02%. Given Intercept Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats Intercept Pharmaceuticals on 10 of the 15 factors compared between the two stocks.